Business context and reporting period
InflaRx N.V. filed an audited Form 20-F for the fiscal year ended December 31, 2018; this is an annual filing, not a standalone fourth-quarter report. The company is a clinical-stage biopharmaceutical developer focused on anti-C5a therapies. Its lead candidate, intravenous IFX-1, was being developed for hidradenitis suppurativa (HS), ANCA-associated vasculitis (AAV) and pyoderma gangrenosum (PG). Financial statements are prepared in euros under IFRS as issued by the IASB.
Financial and operating highlights
| Metric | FY 2018 | FY 2017 |
|---|---|---|
| Product revenue | None | None |
| Research and development expense | €25.0 million | €14.4 million |
| General and administrative expense | €12.8 million | €5.1 million |
| Operating loss | €37.5 million | €19.4 million |
| Net financial result | €7.7 million income | €4.8 million expense |
| Net loss | €29.8 million | €24.2 million |
| Basic and diluted loss per share | €1.19 | €2.60 |
| Operating cash used | €23.7 million | €12.2 million |
| Cash and cash equivalents at year-end | €55.4 million | €123.3 million |
| Marketable securities at year-end | Approximately €101.0 million | None reported |
| Total assets / liabilities / equity at year-end | €159.2 million / €7.8 million / €151.4 million | €124.2 million / €4.8 million / €119.4 million |
There were no product sales, so revenue-based margins are not meaningful. The company reported no financial debt; liabilities were primarily trade and other payables. Cash plus marketable securities totaled approximately €156.4 million at year-end. The reported net financial gain included €8.25 million of foreign-exchange income and €2.18 million of interest income; the foreign-exchange effect may not be realized. Share-based compensation was €12.1 million, including substantial non-cash expense.
Material changes versus the prior year
- R&D expense rose €10.6 million, primarily from clinical research and manufacturing costs for IFX-1 programs and higher personnel costs.
- G&A expense increased €7.6 million, mainly due to personnel and share-based compensation, with additional offering-related and public-company costs.
- Net loss increased €5.6 million despite the swing to positive net financial income, as operating loss widened substantially.
- Operating cash use nearly doubled. Investing cash use increased to €99.5 million, largely reflecting purchases of marketable securities; financing provided €49.6 million, principally from the May 2018 share offering.
- The May 2018 offering included 1.85 million primary shares and generated €49.2 million net proceeds for the company; selling shareholders also sold shares. Year-end shares outstanding were 25,964,379.
Outlook, commentary and key risks
- Management expected 2019 R&D spending to rise significantly. If the HS Phase IIb results supported further development, the estimated cost of an IFX-1 Phase III program was €40–€50 million.
- The 179-patient, placebo-controlled HS Phase IIb trial completed enrollment in November 2018; topline results were expected in Q2 2019. The Phase IIb results were not yet available in this filing.
- The company planned Phase II development in AAV in the United States and Europe; the European study was expected to begin in Q1 2019. A 12-patient exploratory PG study in Canada had received approval in February 2019, with initiation planned for Q2 2019. IFX-2 remained in early preclinical development.
- Management stated in the operating review that cash and cash equivalents would fund operations and capital requirements for at least 24 months. The financial-statement liquidity note, however, described funding for at least 12 months from December 31, 2018. The filing also says existing funds would not cover all planned development through completion and that additional funding may be needed.
- Major risks include clinical efficacy and safety uncertainty, regulatory approval and trial-enrollment risk, reliance on third-party manufacturers and CROs, competition, intellectual-property challenges, and foreign-exchange exposure. The company did not hedge currency risk; a 10% euro weakening against the U.S. dollar was estimated to increase loss by €14.3 million, while a 10% strengthening was estimated to reduce loss by €17.4 million, all else equal.
- Contractual CRO and other non-cancellable operating commitments totaled €29.3 million, of which €19.6 million was due within one year; lease commitments totaled €0.6 million. The company reported no material litigation during the period and no off-balance-sheet arrangements apart from operating leases and certain third-party contracts.
- The audited statements received an unqualified opinion from KPMG. Management concluded disclosure controls and internal control over financial reporting were effective as of year-end; the auditor did not provide an internal-control attestation because of the emerging-growth-company transition relief.
Important facts for investors to verify
- Confirm the actual cash runway and reconcile the filing’s 12-month liquidity-note statement with management’s 24-month assertion.
- Review the HS Phase IIb topline results and subsequent clinical or regulatory updates, including whether the data support the estimated €40–€50 million Phase III program.
- Track clinical progress, costs and financing needs for the U.S. and European AAV studies, the PG study and IFX-2 preclinical work.
- Assess how much reported loss growth reflected non-cash share-based compensation and foreign-exchange movements, and how quickly operating cash use is increasing.
- Monitor marketable-security liquidity and credit quality, the company’s U.S.-dollar exposure, and the €29.3 million of contractual commitments.
- Consider dilution and governance risks: the company may need further financing, and it reported concentrated share ownership and reliance on certain home-country governance exemptions.
- For U.S. investors, review the company’s disclosure that it likely qualified as a passive foreign investment company for 2018 and the associated tax implications.